1863 related articles for article (PubMed ID: 11713762)
1. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
2. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
3. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
4. New prospectives of prostate cancer gene therapy: molecular targets and animal models.
Hsieh CL; Chung LW
Crit Rev Eukaryot Gene Expr; 2001; 11(1-3):77-120. PubMed ID: 11693967
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic vaccines for prostate cancer: a review of clinical data.
Arlen PM; Gulley JL
Curr Opin Investig Drugs; 2005 Jun; 6(6):592-6. PubMed ID: 15988910
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy with poxvirus vectors.
Moroziewicz D; Kaufman HL
Curr Opin Mol Ther; 2005 Aug; 7(4):317-25. PubMed ID: 16121697
[TBL] [Abstract][Full Text] [Related]
7. Pox viral vaccine approaches.
Arlen PM; Kaufman HL; DiPaola RS
Semin Oncol; 2005 Dec; 32(6):549-55. PubMed ID: 16338420
[TBL] [Abstract][Full Text] [Related]
8. [Vaccine therapy of prostate cancer].
Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
[TBL] [Abstract][Full Text] [Related]
9. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
10. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
[TBL] [Abstract][Full Text] [Related]
11. Poxviruses as vectors for cancer immunotherapy.
Kwak H; Hörig H; Kaufman HL
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):161-8. PubMed ID: 12669450
[TBL] [Abstract][Full Text] [Related]
12. Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.
Taylor J; Paoletti E
Prog Vet Microbiol Immunol; 1988; 4():197-217. PubMed ID: 3078866
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
14. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
15. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
16. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry.
Skinner MA; Laidlaw SM; Eldaghayes I; Kaiser P; Cottingham MG
Expert Rev Vaccines; 2005 Feb; 4(1):63-76. PubMed ID: 15757474
[TBL] [Abstract][Full Text] [Related]
17. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
[TBL] [Abstract][Full Text] [Related]
18. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
19. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
[TBL] [Abstract][Full Text] [Related]
20. Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors.
Mastrangelo MJ; Lattime EC
Cancer Gene Ther; 2002 Dec; 9(12):1013-21. PubMed ID: 12522440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
